A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Solid Tumor
Advanced Solid Tumor
Non-small Cell Lung Cancer
SMARCA4-Deficient Tumor

Interventions

DRUG: LY4050784
DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Paclitaxel
DRUG: Nab paclitaxel

Sponsor

Eli Lilly and Company